What are the factors affecting the mound displacement detected in endoscopic treatment failure of vesicoureteral reflux

Year 2024, Volume: 3 Issue: 1, 320 - 324, 29.03.2024

Gökhan Demirtaş , Tuğrul Tiryaki

Abstract

Introductıon: Success rates of endoscopic treatment for vesicoureteral reflux range from 50-100%. Various factors predict outcomes after endoscopic injection. Mound displacement is one of the most critical factors for failure.We observed mound displacement in most of the patients with endoscopic injection failure. We aimed to evaluate predisposing factors for mound displacement in patients with endoscopic injection for vesicoureteral reflux.
Methods: In 2020, operative images were taken and archived in cases where the endoscopic injection was applied due to vesicoureteral reflux. The localization of the bulking agent was evaluated during the redo procedure in 11 patients who were re-admitted due to the failure of the injection procedure. In addition, age, gender, side and degree of reflux, bladder thickness in US, and bladder trabeculation were evaluated.
Results: Local migration of bulking agent was seen in 11 patients at cystoscopy after initial treatment failure. Our repeat endoscopic injection rate was 11/80 (13.75%). Bladder wall thickness and/or trabeculation, constipation, and post-voiding residue (over 20 ml) were significantly higher in patients with mound displacement.
Conclusion: Patients with thick bladder walls with increased PVR and accompanying constipation have the risk of mound displacement. Therefore, we recommend performing a cystoscopy in all cases with recurrence to evaluate the location of the bulking agent. If the mound displacement is noted, we recommend reinjection. Patients with a thick bladder wall, postvoiding residue, and concomitant constipation are at increased risk of bulking agent displacement. If migration of bulking agent is detected, we recommend reinjection with Double HIT or multi-site injection techniques.

Keywords

Vesicoureteral reflux, Children, Endoscopic surgery

References

• 1. Herbst KW, Corbett ST, Lendvay TS, Caldamone AA. Recent trends in the surgical management of primary vesicoureteral reflux in the era of dextranomer/hyaluronic acid. J Urol 2014; 191:1628–33.
• 2. Hacker FM, Frech-Dorfler M, vonRotz M, Rudin C. Endoscopic hyaluronic acid/dextranomer gel implantation is effective as first-line treatment of vesicoureteral reflux in children: a single center experience. Eur J Pediatr Surg 2011;21: 299-303.
• 3. Lackgren G, Stenberg A. Endoscopic treatment of vesicoureteral reflux: current practice and the need for multifactorial assessment. Ther Adv Urol 2009;1:131-41.
• 4. Hoberman A, Greenfield SP, Mattoo TK, Keren R, Mathews R, Pohl HG et al.The RIVUR Trial Investigators, Antimicrobial Prophylaxis for Children with Vesicoureteral Reflux. N Engl J Med. 2014;370:2367–76.
• 5. Dave S, Lorenzo AJ, Khoury AE et al. Learning from the learning curve: factors associated with successful endoscopic correction of vesicoureteral reflux using dextranomer/hyaluronic acid copolymer. J Urol 2008;180:1594–9.
• 6. Puri P, Chertin B, Velayudham M, Dass L, Colhoun Treatment of vesicoureteral reflux by endosmigrationcopic injection of dextranomer/hyaluronic acid copolymer: preliminary results. J Urol 2003;170:1541–4.
• 7. Puri P, Kutasy B, Colhoun E, Hunziker M. Single center experience with endoscopic subureteral dextranomer/hyaluronic acid injection as first line treatment in 1,551 children with intermediate and high grade vesicoureteral reflux. J Urol 2012; 188:1485-9
• 8. Routh JC, Inman BA, Reinberg Y. Dextranomer /hyaluronic acid for pediatric vesicoureteral reflux: systematic review. Pediatrics 2010;125:1010–9.
• 9. Lorenzo AJ, Salle JLP, Barroso U, Cook A, Grober E, Wallis MC, et al. What are the most powerful determinants of endoscopic vesicoureteral reflux correction? Multivariate analysis of a single institution experience during 6 years. J Urol 2006;176:1851–5.
• 10. Yucel S, Gupta A, Snodgrass W. Multivariate analysis of factors predicting success with dextranomer/hyaluronic acid injection for vesicoureteral reflux. J Urol 2007; 177:1505–9. doi: 10.1016/j.juro.2006.11.077.
• 11. Routh JC, Reinberg Y. Predicting success in the endoscopic management of pediatric vesicoureteral reflux. Urology 2010;76:195–8.
• 12. Haid B, Berger C, Roesch J, Becker T , Koen M, Langsteger W.et al. Persistence and recurrence of vesicoureteric reflux in children after endoscopic therapy — implications of a risk-adapted follow-up. Cent Eur J Urol 2015;68:389–95.
• 13. Chandrasekharam VVS. Do Volume of Injection and Learning Curve Influence the results of Endoscopic Correction of Vesicoureteric Reflux Using Dextranomer/Hyaluronic Acid? A Single Surgeon Experience. J Laparoendosc Adv Surg Tech A 2021;31:220-224.
• 14. Lavelle MT, Conlin MJ, Skoog SJ. Subureteral injection of Deflux for correction of reflux: analysis of factors predicting success. Urology 2005;65:564–7.
• 15. Capozza N, Lais A, Nappo S, Caione P. The role of endoscopict reatment of vesicoureteral reflux: a 17-year experience. J Urol 2004;172:1626–8.
• 16. Akbal C, Genc Y, Burgu B, Ozden E, Tekgul S. Dysfunctional voiding and incontinence scoring system: quantitative evaluation of incontinence symptoms in pediatric population.J Urol. 2005 Mar;173(3):969-73
• 17. Palsson OS, Whitehead WE, van Tilburg MA, et al. Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. Gastroenterology, 13 Feb 2016, :S0016-5085(16)00180-3
• 18. Müller L , Bergström T, Hellström M, Svensson E, Jacobsson B. Standardized ultrasound method for assessing detrusor muscle thickness in children J Urol. 2000 Jul;164(1):134-8.
• 19. Elder JS, Diaz M, Calamone AA, Greenfield S, Hurwitz R, Kirsch A. et al. Endoscopic therapy for vesicoureteral reflux: a meta-analysis. I. Reflux resolution and urinary tractin fection. J Urol. 2006;175:716–22. doi: 10.1016/S0022-5347(05)00210-7.
• 20. Capozza N, Lais A, Matarazzo E, Nappo S, Patricolo M, Caione P. Influence of voiding dysfunction on the outcome of endoscopic treatment for vesicoureteral reflux. J Urol 2002;168:1695–8.
• 21. Trsinar B, Cotic D, Oblak C. Possible causes of unsuccessful endoscopic collagen treatment of vesicoureteral reflux in children. Eur Urol 1999;36:635–9.
• 22. Kirsch AJ. Injection therapy for reflux: Why it Works and why it fails. J Urol 2012;188:16–7.
• 23. Higham-Kessler J, Reinert SE, Snodgrass WT, Hensle TW, Koyle MA, Hurwitz RS et al. A review of failures of endoscopictreatment of vesicoureteral reflux with dextranomer microspheres. J Urol 2007;177:710–5.
• 24. Te-Lu Yap, Yong Chen , Shireen A. Nah, Caroline Choo Phaik Ong, Anette Jacobsen, Yee. Low STING versus HIT technique of endoscopic treatment for vesicoureteral reflux: A systematic review and meta-analysis. J Pediatric Surgery 2016;51 2015–2020.
• 25. Sean T. Watters , Jennifer Sung , Steven J. Skoog. Endoscopic treatment for vesicoureteral reflux: How important is technique? J Pediatric Urology 2013;9, 1192-1197
• 26. Jonathan F. Kalisvaart, Hal C. Scherz, ScottCuda, Jonathan D. Kaye, Andrew J. Kirsch Intermediate to long-term follow-up indicates low risk of recurrence after Double HIT endoscopic treatment for primary vesico-ureteral reflux J Pediatr Urology 2012: 8;359-365.